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Objective: To determine whether low HDL-C is a risk factor for adverse cardiovascular events in patients
with known CAD.
Methods: We evaluated 10,391 patients who underwent PCI from January 2005 to December 2007. In
total, 3838 (36.9%) patients had low HDL-C (HDL-C <40 mg/dL in males and <50 mg/dL in females) and
6553 (63.1%) patients had normal HDL-C based on measurements on admission.
Results: The unadjusted 5-year incidence of major adverse cardiac events (MACE: composite of cardio-
vascular death, myocardial infarction or stroke) was signiﬁcantly higher in the low HDL-C group than in
the normal HDL-C group (17.6% vs. 14.0%, P < 0.0001). However, after adjusting for confounders, low
HDL-C was not associated with a higher risk of MACE (adjusted hazard ratio [HR] 1.07, 95% conﬁdence
interval (CI) 0.97e1.19; P ¼ 0.19). There was no signiﬁcant interaction between the effect of low HDL-C on
MACE and several subgroup factors including age, sex, clinical presentation of CAD, statins use, serum
low-density lipoprotein cholesterol level, and serum triglycerides level.
Conclusion: Low HDL-C, as compared with normal HDL-C, was not associated with higher 5-year risk of
MACE in patients who underwent PCI.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of coronary events in patients without known
coronary artery disease (CAD) appears to be inversely related to
serum HDL-cholesterol (HDL-C) concentration, with low levels of
HDL-C being associated with increased coronary risks [1,2]. In
addition, premature CAD is common in patients with primary or
inherited disorders with low serum HDL-C [3e5] and low HDL-C
levels are more commonly seen in patients with a ﬁrstcular of Medicine, Graduate
wahara-cho, Sakyo-ku, Kyoto
o).
Ireland Ltd. This is an open accessmyocardial infarction (MI) than in age-matched controls without
CAD [3].
Even among patients with stable CAD treated with statin ther-
apy, lower HDL-C levels are associated with higher risks of car-
diovascular events [6]. Moreover, in a post-hoc analysis of 2193
individuals with stable disease, who participated in the COURAGE
trial, and weremanaged on optimal medical therapy, the rate of all-
cause death or MI was 33% lower in the highest compared with the
lowest HDL-C quartile [7].
Conversely, not all studies have found that HDL-C is predictive of
future events in patients with established CAD treated with statin
therapy. It is known that intensive statin therapy abolished the
inverse association between HDL-C and vascular events in an
analysis of the JUPITER (Justiﬁcation for the Use of Statins inarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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A similar lack of an inverse relationship was repeatedly observed in
patients receiving intensive statin therapy [7,9].
It is still controversial whether low HDL-C inﬂuences cardio-
vascular outcomes, especially in patients with known CAD
receiving current optimized treatments. Therefore, we sought to
evaluate this in a large Japanese observational database of patients
who underwent ﬁrst coronary revascularization procedures.2. Methods
2.1. Study population
The CREDO-Kyoto (Coronary REvascularization Demonstrating
Outcome Study in Kyoto) PCI/CABG registry cohort-2 is a physician-
initiated non-company sponsored multi-center registry enrolling
consecutive patients undergoing ﬁrst coronary revascularization at
26 centers in Japan between January 2005 and December 2007. The
relevant review boards or ethics committees at all 26 participating
centers approved the research protocol. Because of retrospective
enrollment, written informed consent from the patients was
waived; however, we excluded those patients who refused partic-
ipation in the study when contacted for follow-up.
The study design and patient enrollment of the CREDO-Kyoto
PCI/CABG registry cohort-2 were described in detail previously
[10]. The current post-hoc subanalysis of the registry intended to
evaluate the inﬂuence of serum HDL-C levels during the index
hospitalization on long-term clinical outcomes in patients who
underwent their ﬁrst PCI. Among 15,939 patients who underwent
PCI or coronary artery bypass grafting (CABG) as a ﬁrst coronary
revascularization procedure, 13,144 patients underwent PCI.
Excluding 86 patients who refused study participation, 342 pa-
tients who died during the index hospitalization, and 2325 patients
inwhom the level of HDL-C and low-density lipoprotein cholesterol
(LDL-C) could not be identiﬁed during the index hospitalization,
10,391 patients were included in the present analysis (Fig. 1). To
evaluate the impact of serum HDL-C levels on clinical outcomes,Fig. 1. Study ﬂpatients were divided into two groups according to the level of
HDL-C (low HDL-C in males <40 mg/dL and in females <50 mg/dL)
at time of admission for the index hospitalization. There were 3838
patients (36.9%) in the low HDL-C group and 6553 patients (63.1%)
in the normal HDL-C group.2.2. Deﬁnitions
Deﬁnitions of baseline clinical characteristics were as described
previously [10]. The primary outcome measure for the current
analysis was a composite of MACE (cardiovascular death, MI, or
stroke). Secondary outcome measures included the individual
components of the composite, all-cause death, target-lesion
revascularization (TLR), coronary revascularization other than
TLR, and any coronary revascularization.
Death was regarded as being cardiac in origin unless obvious
non-cardiac causes could be identiﬁed. Vascular death was
deﬁned as death related to aortic, cerebral, renal, or peripheral
vascular diseases. MI was deﬁned according to the deﬁnition in
the Arterial Revascularization Therapy Study [11]. Within 1
week of the index procedure, only Q-wave MI was adjudicated
as MI. Stroke during follow-up was deﬁned as ischemic or
hemorrhagic stroke requiring hospitalization with symptoms
lasting >24 h.
The recommended antiplatelet regimen was aspirin (81 mg/
day) indeﬁnitely and thienopyridine (ticlopidine 200 mg/day or
clopidogrel 75 mg/day) for 3 months. Duration of thienopyridine
administration was left to the discretion of each attending physi-
cian. For statins therapy, we did not set indications for using sta-
tins, and statin use was left to the discretion of each attending
physician. Demographic, angiographic, and procedural data were
collected from hospital charts or databases according to pre-
speciﬁed deﬁnitions in each participating center by experienced
clinical research coordinators in the study management center.
Follow-up data were obtained from hospital charts or by con-
tacting patients or referring physicians. Scheduled staged PCI
procedures performed during the index hospitalization or within 3ow chart.
Table 1
Baseline characteristics: low HDL-C vs. normal HDL-C groups.
Low HDL-C Normal HDL-C P value
N ¼ 3838 N ¼ 6553
Clinical characteristics
Age (years) 68.4 ± 11.2 67.6 ± 10.8 <0.001
75 yearsa 1237 (32%) 1885 (29%) <0.001
a
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events but were included in the index procedure. Clinical events
such as cardiovascular death, MI and stroke were adjudicated from
the original source documents by a clinical events committee.
Follow-up intervals were calculated from the day of the index PCI
procedure. Median follow-up duration was 1870 days (inter-
quartile range [IQR] 1590e2167 days).Male 2409 (63%) 5051 (77%) <0.001
BMI 24.1 ± 3.6 23.6 ± 3.4 <0.001
<25.0a 2465 (64%) 4559 (70%) <0.001
Acute myocardial infarctiona 1509 (39%) 2138 (33%) <0.001
Hypertensiona 3202 (83%) 5403 (82%) 0.20
Diabetes mellitusa 1571 (41%) 2302 (35%) <0.001
On insulin therapy 331 (8.6%) 432 (6.6%) <0.001
Current smokinga 1297 (34%) 2014 (31%) <0.001
Heart failurea 854 (22%) 992 (15%) <0.001
Mitral regurgitation grade 3/4a 168 (4.4%) 220 (3.4%) 0.009
Ejection fraction (%) 57.6 ± 13.0 59.4 ± 12.6 <0.001
Prior myocardial infarctiona 461 (12%) 577 (8.8%) <0.001
Prior strokea 432 (11%) 604 (9.2%) <0.001
Peripheral vascular diseasea 293 (7.6%) 450 (6.9%) 0.14
Multivessel disease 2252 (59%) 3447 (53%) <0.001
Target of proximal LADa 2137 (55%) 3809 (58%) 0.02
Unprotected LMCA diseasea 166 (4.3%) 220 (3.4%) 0.02
Target of CTOa 454 (12%) 746 (11%) 0.49
eGFR < 30, not on dialysisa 204 (5.3%) 152 (2.3%) <0.001
Dialysisa 161 (4.2%) 176 (2.7%) <0.001
Atrial ﬁbrillationa 353 (9.2%) 487 (7.4%) 0.002
Anemia (Hb < 11 g/dl)a 574 (15%) 534 (8%) <0.001
Platelets <100  109/La 70 (1.8%) 70 (1.1%) 0.002
COPDa 152 (4.0%) 349 (3.8%) 0.68
Liver cirrhosisa 113 (2.9%) 141 (2.2%) 0.01
Malignancya 314 (8.2%) 594 (9.1%) 0.12
Baseline lipid levels
Total cholesterol (mg/dl) 181 ± 40.4 197 ± 38.7 <0.001
TG (mg/dl)a 118 (81e171) 102 (70e145) <0.001
HDL-C (mg/dl)a 36.4 ± 6.3 54.6 ± 11.9 <0.001
LDL-C (mg/dl)a 117 ± 35.5 119 ± 34.7 0.01
Baseline medication
Thienopyridine 3746 (98%) 6410 (98%) 0.48
Aspirin 3797 (99%) 6488 (99%) 0.71
Cilostazola 790 (21%) 1105 (17%) <0.001
Statina 2027 (53%) 3654 (56%) 0.004
Beta-blockera 1365 (36%) 1963 (30%) <0.001
ACEI/ARBa 2372 (62%) 3845 (59%) 0.002
Calcium-channel blockera 1504 (40%) 2800 (43%) <0.001
Nitratesa 1317 (34%) 2190 (33%) 0.35
Nicorandila 1007 (26%) 1623 (24%) 0.10
a2.3. Statistical analysis
Data are presented as numbers and percentages or mean
value ± standard deviation ormedian and IQR. Categorical variables
were compared using chi-square test. Continuous variables were
compared using Student's t-test or Wilcoxon rank sum test based
on their distributions. Cumulative incidences of events after the
index PCI were estimated using the KaplaneMeier method, and
differences between groups were assessed using the log-rank test.
We used Cox proportional hazard models to estimate risk of low
HDL-C relative to normal HDL-C for the primary and secondary
outcome measures after adjusting for differences in patient char-
acteristics, procedural factors, and medical therapies between
groups. Consistent with our previous report, we chose 34 clinically
relevant factors (Table 1) as risk-adjusting variables. Continuous
variables were dichotomized using clinically meaningful reference
values or median values. Centers were included in the model as
stratiﬁcation variables. Effects of low HDL-C relative to normal
HDL-C on clinical outcomes were expressed as hazard ratio (HR)
and 95% conﬁdence interval (CI). Subgroup analyses were also
conducted in accordance with several pre-speciﬁed subgroup fac-
tors including age (75 years and <75 years), sex, clinical presen-
tation of CAD (stable CAD and acute coronary syndrome [ACS]),
administration of statins at the time of discharge from the index
hospitalization, serum LDL-C level, and serum triglycerides (TG)
level. The inﬂuences of lipid abnormalities other than lowHDL-C on
the primary outcome measure were also assessed according to the
levels of LDL-C (high LDL-C > 100 mg/dL) and TG (high
TG  150 mg/dL).
All analyses were conducted with the use of JMP 10.0 (SAS
Institute Inc, Cary, NC, USA). All the statistical analyses were two-
tailed, and P values <0.05 were considered statistically signiﬁcant.Warfarin 352 (9.2%) 492 (7.5%) 0.003
Proton-pump inhibitora 1124 (29%) 1557 (23%) <0.001
H2-blockera 1029 (27%) 1716 (26%) 0.49
Values are mean ± SD or median (interquartile range).
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor
blockers; BMI, bodymass index; COPD, chronic obstructive pulmonary disease; CTO,
chronic total occlusion; eGFR, estimated glomerular ﬁltration rate; Hb, hemoglobin;
HDL-C, high-density lipoprotein cholesterol; LAD, left anterior descending artery;
LDL-C, low-density lipoprotein cholesterol; LMCA, left main coronary artery; TG,
triglycerides.
a Potential independent variables selected for multivariate analysis.3. Results
3.1. Baseline characteristics and medications in low HDL-C versus
normal HDL-C groups
According to their serum levels of HDL-C, the total population of
10,391 patients was divided into 3838 patients with lowHDL-C and
6553 with normal HDL-C. Because of the large number of patients
and the observational study design, signiﬁcant differences were
observed in many variables in the baseline characteristics of the
low HDL-C and normal HDL-C groups, as shown in Table 1.
Compared with patients with normal HDL-C, patients with low
HDL-C were older, there more females and these patients had
higher rates of higher body mass index (BMI), ACS presentation,
diabetes mellitus, current smoking, heart failure, prior MI, prior
stroke, renal failure, atrial ﬁbrillation, multivessel CAD, anemia, and
liver cirrhosis. TG levels were signiﬁcantly higher in patients in the
low HDL-C group, whereas total cholesterol was signiﬁcantly
higher in patients in the normal HDL-C group. Cilostazol, angio-
tensin converting enzyme inhibitors/angiotensin receptor blockers,
beta blockers, proton-pump inhibitors, and warfarin were used
more often in the low HDL-C group, whereas statins and calcium
channel blockers were more often used in the normal HDL-C group.3.2. Cardiovascular outcomes: low HDL-C versus normal HDL-C
The cumulative 5-year incidence of MACE was signiﬁcantly
higher in the low HDL-C group than in the normal HDL-C group
(17.6% vs. 14.0%, log-rank P < 0.001). However, after adjusting for
potential confounders, the excess risk of low HDL-C relative to
normal HDL-C for MACE was no longer signiﬁcant (HR 1.07 [95% CI
0.97e1.19], P ¼ 0.19) (Table 2 and Fig. 2). Adjusted risks of low HDL-
C relative to normal HDL-C for the individual components of MACE
(all-cause death, cardiovascular death, MI, and stroke) were also
not signiﬁcant (Table 2).
On the other hand, the cumulative 5-year incidence of and
adjusted risk of any coronary revascularization was signiﬁcantly
Table 2
Event rates and risks of low HDL-C relative to normal HDL-C.
Low HDL-C (N ¼ 3838)
no. of patients with event
(cumulative 5-year incidence)
Normal HDL-C (N ¼ 6553)
no. of patients with event
(cumulative 5-year incidence)
Unadjusted HR
(95% CI)
P value Adjusted
HR (95% CI)
P value
MACE (cardiovascular death,
MI and stroke)
657 (17.6%) 951 (14.0%) 1.29 (1.17e1.43) <0.001 1.07 (0.97e1.19) 0.19
All-cause death 690 (18.0%) 909 (13.9%) 1.32 (1.19e1.45) <0.001 1.07 (0.96e1.19) 0.22
Cardiovascular death 333 (8.7%) 415 (6.3%) 1.39 (1.20e1.60) <0.001 0.99 (0.85e1.16) 0.92
Myocardial infarction 291 (7.6%) 438 (6.7%) 1.15 (0.99e1.33) 0.07 1.19 (0.96e1.31) 0.16
Stroke 250 (6.5%) 364 (5.6%) 1.20 (1.02e1.40) 0.03 1.06 (0.90e1.26) 0.47
TLR 867 (22.6%) 1386 (21.1%) 1.09 (1.00e1.19) 0.04 1.09 (0.99e1.19) 0.07
Coronary revascularization
other than TLR
915 (23.8%) 1406 (21.5%) 1.14 (1.05e1.24) 0.002 1.12 (1.03e1.22) 0.01
Any coronary revascularization 1409 (36.7%) 2245 (34.3%) 1.11 (1.03e1.18) 0.003 1.10 (1.02e1.18) 0.009
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiac events (cardiovascular death, myocardial infarction or
stroke); TLR, target lesion revascularization.
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(36.7% vs. 34.3%, log-rank P ¼ 0.003, and HR 1.10 [95% CI 1.02e1.18],
P ¼ 0.009) (Table 2 and Fig. 3).3.3. Subgroup analysis
With regard to MACE, there was no signiﬁcant interaction
between the effect of low HDL-C and several subgroup factors
including age (75 years and <75 years), sex, clinical presentation
of CAD (stable CAD and ACS), administration of statins at time of
discharge from the index hospitalization, serum LDL-C level, and
serum TG level (Supplemental Fig. A). For any coronary revascu-
larization, there was a signiﬁcant interaction between the effect of
low HDL-C and age (Supplemental Fig. B). Low HDL-C was asso-
ciated with a signiﬁcantly higher risk of any coronary revascu-
larization in patients <75 years of age, but not in patients 75
years of age.Fig. 2. Crude and adjusted event curves for the primary outcome measure; low HDL-C ve
lipoprotein cholesterol; MACE, major adverse cardiac events; MI, myocardial infarction.3.4. The relationship between MACE and other lipid parameters
In order to assess the inﬂuence of lipid parameters other than
HDL-C on MACE, we evaluated the relationship between MACE and
LDL-C levels or TG levels (Supplemental Table). In univariate ana-
lyses, both high LDL-C levels (>100 mg/dL) and high TG levels
(>150 mg/dL) were signiﬁcantly associated with lower incidences
of MACE (14.5% vs. 17.2%, log-rank P < 0.0001, and 13.4% vs. 16.0%,
log-rank P ¼ 0.0005, respectively). However, after adjusting for
confounders, neither high LDL-C level nor high TG level were
associated with an increased risk of MACE (HR 1.03 [95% CI
0.93e1.15] P ¼ 0.49, and HR 1.02 [95% CI 0.91e1.16] P ¼ 0.70,
respectively).
4. Discussion
The main ﬁnding of this study was that low HDL-C levels, as
compared with normal HDL-C levels, were not associated with arsus normal HDL-C: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
Fig. 3. Crude and adjusted event curves for any revascularization; low HDL-C versus normal HDL-C.
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Although the adjusted risk of all coronary revascularization pro-
cedureswas signiﬁcantly higher in the lowHDL-C group than in the
normal HDL-C group, this is secondary outcome andmay have been
because subjects had a higher incidence of coronary revasculari-
zation procedures than that of MACE.
HDL-C is thought to reduce the risk of atherosclerotic cardio-
vascular diseases. This proposition is based on numerous epide-
miologic studies, which have suggested an inverse relationship
between HDL-C concentration and the risk of cardiovascular dis-
ease [12]. As far as secondary prevention is concerned, many
different studies have shown that low levels of HDL-C predict car-
diovascular risk [13], are independently associated with acute
coronary syndrome in patients hospitalized for chest pain [14], and
represent a poor prognosis in patients with acute coronary syn-
drome [15e17]. Other reports have indicated that the concentration
of HDL-C prior to PCI is an independent predictor for restenosis and
revascularization of stents [18e20], peri-procedural acute
myocardial infarction [21], and 1-year mortality [22]. Similar re-
sults have also been shown for the carotid arteries [23].
Conversely, several recent trials including JUPITER [8], PROVE IT-
TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection
Therapy-Thrombolysis In Myocardial Infarction 22) [9], and SMART
(Second Manifestation of ARTerial disease) [7] have reported an
absence of an association between low HDL-C and cardiovascular
events in high-risk patients treated with aggressive statin therapy,
and our results conﬁrmed these ﬁndings in Japanese patients who
underwent a ﬁrst coronary revascularization. The effect of low
HDL-C on cardiovascular outcomes might be different according to
the presence or absence of lipid-lowering therapy and the intensity
of statin therapy. In the SMART study, low HDL-C was still associ-
ated with an increased risk of recurrent cardiovascular events
among patients who were not receiving lipid-lowering medication
or those being treated with a usual dose lipid-lowering medication
[7]. Similar observations were reported from the TNT (Treating toNew Targets) trial [24], in which HDL-C was associated with car-
diovascular events in the atorvastatin 10 mg group, but not in the
atorvastatin 80 mg group.
Therefore, a possible hypothesis that can reconcile the results of
previous epidemiological studies and those of the recent reports,
including ours, is that HDL-C levels may be predictive of MACE,
when use or intensity of statin treatment is low, as was observed in
subjects in the primary prevention studies, and in those patients in
the placebo groups in both JUPITER and SMART trials, or were in the
atorvastatin 10 mg group in the TNT study.
While, our subgroup analysis indicated that lowHDL-C levels, as
compared with normal HDL-C levels, was not associated with a
higher 5-year risk of MACE in patients even without statin treat-
ment. In this context, another possible reasonwhy lowHDL-C is not
a risk factor in patients with known CAD might be the possibility
that HDL functionality is already impaired in these patients. It has
been shown that HDL functionality in patients with ischemic heart
disease is impaired and HDL functionality, but not the plasma levels
of HDL-C, seems to be the target to evaluate cardiovascular event
risk [25e27]. Mechanistically, the capacity of HDL-C to mediate
cholesterol efﬂux from lipid-laden macrophages has been reported
to be impaired after substantial oxidative modiﬁcation of HDL-C by
myeloperoxidase (MPO) [28,29]. It was also shown that the capacity
of HDL-C to prevent the proinﬂammatory effects of LDL-C was
impaired in patients with CAD [30], and reduced paraoxonase 1
(PON1) activity was identiﬁed as onemolecular mechanism leading
to the loss of anti-inﬂammatory effects of HDL-C in patients with
stable CAD or an ACS [25]. It has also been demonstrated that MPO,
PON1 and HDL form a functional ternary complex and that MPO
promotes impairment of PON1 and apoA-I function [31].
Our subgroup analysis also showed that higher LDL-C levels
(>100 mg/dL) was not associated with an increased risk of MACE.
As shown in our previous study, compared with standard statin
therapy, aggressive statin therapy was associated with lower car-
diovascular risk and that the risk of cardiovascular events was
M. Izuhara et al. / Atherosclerosis 242 (2015) 632e638 637comparable, irrespective of achieved LDL-C level, evenwhen LDL-C
< 120 mg/dl was achieved in the same study population [32]. Thus,
“the lower the better” may not be always applicable, but “make it
lower with statins” should always be addressed in secondary pre-
vention, even in relatively low-risk patients, including Japanese
patients.
The failure of recent clinical trials to show an effect of raising
HDL-C as a therapeutic strategy for the prevention of atheroscle-
rosis may also suggest that low HDL-C is not a risk in known CAD
patients. In fact, trials evaluating cholesterol ester transfer protein
(CETP) inhibitors such as torcetrapib or dalcetrapib could not
demonstrate beneﬁcial results despite large increases in HDL-C
levels [33,34]. The Atherothrombosis Intervention in Metabolic
Syndrome with Low HDL/High Triglycerides: Impact on Global
Health Outcome (AIM-HIGH) trial and Second Heart Protection
Study (HPS-2 THRIVE) failed to show beneﬁcial effects of niacin on
cardiovascular events in patients treated optimally at low levels of
LDL-C [35,36]. However, the failure of these trials of therapies that
aimed to raise HDL-C might be due to the possibility that HDL-C
levels increased by CETP inhibitors or niacin were not function-
ally ideal for the treatment of atherosclerosis [37,38].
It has been shown that genetic mechanisms that raise plasma
HDL-C do not seem to lower the risk of MI, challenging the concept
that raising HDL-C will translate into a reduction in the risk of MI
[39]. However, this analysis also does not take HDL-C functionality
into account either. It is possible that all kinds of HDL-C, including
‘dysfunctional’ HDL-C, were elevated in those who have genetic
variants that raise HDL-C.
There is plenty of experimental evidence that HDL-C has
beneﬁcial effects, including anti-inﬂammatory and anti-oxidative
effects, as well as reverse cholesterol transport [40]. Improving
HDL functionality instead of simply increasing HDL-C levels might
be much more important. Many HDL-C-based interventions, such
as apoA-I-based compounds [41], apoA-I upregulators [42], ABC-
transporter up-regulators, including microRNA-mediated thera-
peutics [43,44], synthetic liver X receptor agonists [45] and lectin-
cholesterol acyltransferase-based therapy [46], are under devel-
opment and are still holding great promise for the future.5. Study limitations
There are several important limitations in this study. First, our
ﬁndings are subject to confounding factors because of the obser-
vational retrospective nature of the study. Second, we excluded
patients who died during the index hospitalization because this
study aimed to evaluate long term outcome of patients who un-
derwent ﬁrst coronary revascularization procedures. Third, we
used only plasma lipid levels measured at start of the study. It is
possible that using lipid levels from follow-up data rather than
baseline data might have resulted in different outcomes. Fourth,
only data about baseline medications were available, which was
likely to have changed during follow-up.6. Conclusion
Low HDL-C levels, as compared with normal HDL-C levels, were
not associated with a higher 5-year risk of MACE in patients who
underwent PCI.Funding sources
This study was supported by the Pharmaceuticals and Medical
Devices Agency (PMDA) of Japan.Disclosures
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Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.atherosclerosis.2015.05.010.
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